Essential cookies by default. The browser ID, load-time metrics and error replays only run if you choose "Accept all".
Head-to-head evidence comparison — which supplement is right for you?
Empagliflozin vs Orforglipron: they're closely matched on evidence (4.5 vs 5.5/10); they're alternatives for manage blood sugar — the best pick depends on your goals. Take the 2-minute quiz for a pick tailored to your goals.
Empagliflozin and Orforglipron are closely matched across evidence, studies, and safety.
Verdict
Helped
7 of 7 studies with measurable effects showed benefit.
Top outcomes
Verdict
Too few graded studies
1 of 1 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Empagliflozin and Orforglipron have evidence — compare verdict strength side-by-side.
A source-matched dose range is not available for this product and use.
If this treatment was prescribed for you, follow your prescriber’s directions. Do not change prescribed treatment because this page has no matched dose range.
Morning
Oral tablet (empagliflozin)
Use only as prescribed for the exact authorised formulation and indication, following its label and the treating clinician’s plan. No self-directed dose is recommended here.
Any time of day
Oral tablet (Foundayo, US prescription)
Weeks
Months to years
Months to years
Weeks to months
Weeks to months
Months (titrated)
Throughout use
Especially during dose escalation
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine (2015) · RCT · n=7020
EMPA-REG OUTCOME randomized trial in high-CV-risk type-2 diabetics
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Circulation (2018) · RCT
Randomized evidence of empagliflozin benefit in established cardiovascular disease
Empagliflozin in Patients with Chronic Kidney Disease.
The New England journal of medicine (2023) · RCT
EMPA-KIDNEY randomized trial in a broad chronic-kidney-disease population
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1).
N Engl J Med (2025) · RCT · n=3127
Phase-3 multinational double-blind RCT in 3,127 adults with obesity WITHOUT diabetes; once-daily oral orforglipron 6/12/36 mg vs placebo for 72 weeks
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1).
N Engl J Med (2025) · RCT · n=559
Phase-3 double-blind RCT in 559 adults with early type 2 diabetes managed by diet/exercise; once-daily oral orforglipron 3/12/36 mg vs placebo for 40 weeks
Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.
Lancet (2026) · RCT · n=962
Phase-3 non-inferiority RCT (n=962) in type 2 diabetes inadequately controlled on metformin; once-daily oral orforglipron 3/12/36 mg vs dapagliflozin 10 mg over 40 weeks
Both Empagliflozin and Orforglipron are closely matched — the best choice depends on your specific health goals.
For manage blood sugar, Orforglipron has a higher relevance score (70 vs 62).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.